|
Compound class:
Synthetic organic
Comment: SM-27 is a small molecule-drug conjugate (SMDC) [2]. It is made up of a ligand that targets aldo-keto reductase family 1 member C3 (AKR1C3) inside tumour cells, with a cathepsin B-cleavable linkage to the cytotoxic agent gemcitabine. The linker contains a valine-alanine dipeptide bridge that is specifically recognized and cleaved by cathepsin B (CTSB; which is highly expressed by tumour cells) [1,3]. SM-27 is intended to selectively deliver the chemotherapeutic to tumour cells, whilst reducing off-target or bystander toxicity.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| AKR1C3 and cathepsin B must both be present in the cells to trigger the antitumour activity of SM-27 [2]. SM-27 is active against xenograph tumours in vivo. |
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||